

# Mucormycosis- Market Insights, Epidemiology and Market Forecast 2028

<https://marketpublishers.com/r/M8BFA289901EN.html>

Date: June 2019

Pages: 101

Price: US\$ 5,980.00 (Single User License)

ID: M8BFA289901EN

## Abstracts

### REPORT SUMMARY

'Mucormycosis- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering?

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

### Mucormycosis Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Mucormycosis in the US, Europe, and Japan are also provided in the report.

### Mucormycosis Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies,

survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

### Mucormycosis Product Profiles & Analysis

This part of the Mucormycosis report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

### Mucormycosis Market Outlook

The Mucormycosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

### Mucormycosis Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

### Mucormycosis Report Insights

Patient Population in Mucormycosis

Therapeutic Approaches in Mucormycosis

Mucormycosis Pipeline Analysis

Mucormycosis Market Size and Trends

## Mucormycosis Market Opportunities

### Impact of upcoming Therapies in Mucormycosis

## Mucormycosis Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

## Mucormycosis Report Assessment

Current Treatment Practices in Mucormycosis

Unmet Needs in Mucormycosis

Detailed Mucormycosis Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

## Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Mucormycosis market

Organize sales and marketing efforts by identifying the best opportunities for Mucormycosis market

To understand the future market competition in the Mucormycosis market.

**Note:** We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Contents

### **1 KEY INSIGHTS**

### **2 MUCORMYCOSIS MARKET OVERVIEW AT A GLANCE**

2.1 Market Share (%) Distribution of Mucormycosis in 2018

2.2 Market Share (%) Distribution of Mucormycosis in 2028

### **3 MUCORMYCOSIS: DISEASE BACKGROUND AND OVERVIEW**

3.1 Introduction

3.2 Symptoms

3.3 Etiology

3.4 Risk Factor

3.5 Pathophysiology

3.6 Diagnosis

3.7 Treatment

### **4 EPIDEMIOLOGY AND PATIENT POPULATION**

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Mucormycosis in 7MM

4.3. Total Prevalent Patient Population of Mucormycosis in 7MM – By Countries

### **5 EPIDEMIOLOGY OF MUCORMYCOSIS BY COUNTRIES (2016-2028)**

5.1 United States- Epidemiology (2016-2028)

5.1.1 Assumptions and Rationale

5.1.2 Prevalent/Incident Cases of Mucormycosis in the United States

5.1.3 Sub-Type Specific cases of Mucormycosis in the United States

5.1.4 Sex- Specific Cases of Mucormycosis in the United States

5.1.5 Diagnosed Cases of Mucormycosis in the United States

5.1.6 Treatable Cases of Mucormycosis in the United States

5.2 EU5 Countries

5.2.1 Germany

5.2.1.1 Assumptions and Rationale

5.2.1.2 Prevalent/Incident Cases of the of Mucormycosis in the Germany

5.2.1.3 Sub-Type Specific cases of Mucormycosis in the Germany

- 5.2.1.4 Sex- Specific Cases of the Mucormycosis in the Germany
- 5.2.1.5 Diagnosed Cases of the Mucormycosis in the Germany
- 5.2.1.6 Treatable Cases of the Mucormycosis
- 5.2.2 France
  - 5.2.2.1 Assumptions and Rationale
  - 5.2.2.2 Prevalent/Incident Cases of the of Mucormycosis in the France
  - 5.2.2.3 Sub-Type Specific cases of Mucormycosis in the France
  - 5.2.2.4 Sex- Specific Cases of the Mucormycosis in the France
  - 5.2.2.5 Diagnosed Cases of the Mucormycosis in the France
  - 5.2.2.6 Treatable Cases of the Mucormycosis
- 5.2.3 Italy
  - 5.2.3.1 Assumptions and Rationale
  - 5.2.3.2 Prevalent/Incident Cases of the of Mucormycosis in the Italy
  - 5.2.3.3 Sub-Type Specific cases of Mucormycosis in the Italy
  - 5.2.3.4 Sex- Specific Cases of the Mucormycosis in the Italy
  - 5.2.3.5 Diagnosed Cases of the Mucormycosis in the Italy
  - 5.2.3.6 Treatable Cases of the Mucormycosis
- 5.2.4 Spain
  - 5.2.4.1 Assumptions and Rationale
  - 5.2.4.2 Prevalent/Incident Cases of the of Mucormycosis in the Spain
  - 5.2.4.3 Sub-Type Specific cases of Mucormycosis in the Spain
  - 5.2.4.4 Sex- Specific Cases of the Mucormycosis in the Spain
  - 5.2.4.5 Diagnosed Cases of the Mucormycosis in the Spain
  - 5.2.4.6 Treatable Cases of the Mucormycosis
- 5.2.5 United Kingdom
  - 5.2.5.1 Assumptions and Rationale
  - 5.2.5.2 Prevalent/Incident Cases of the of Mucormycosis in the United Kingdom
  - 5.2.5.3 Sub-Type Specific cases of Mucormycosis in the United Kingdom
  - 5.2.5.4 Sex- Specific Cases of the Mucormycosis in the United Kingdom
  - 5.2.5.5 Diagnosed Cases of the Mucormycosis in the United Kingdom
  - 5.2.5.6 Treatable Cases of the Mucormycosis
- 5.3 Japan
  - 5.3.1 Assumptions and Rationale
  - 5.3.2 Prevalent/Incident Cases of the of Mucormycosis in the Japan
  - 5.3.3 Sub-Type Specific cases of Mucormycosis in the Japan
  - 5.3.4 Sex- Specific Cases of the Mucormycosis in the Japan
  - 5.3.5 Diagnosed Cases of the Mucormycosis in the Japan
  - 5.3.6 Treatable Cases of the Mucormycosis

## **6 CURRENT TREATMENT & MEDICAL PRACTICES**

- 6.1 Treatment Algorithm
- 6.2 Treatment Guidelines

## **7 UNMET NEEDS**

## **8 MARKETED PRODUCT**

- 8.1 Drug A: Company
  - 8.1.1 Drug Description
  - 8.1.2 Mechanism of Action
  - 8.1.3 Clinical Trials Details
  - 8.1.4 Advantages & Disadvantages
  - 8.1.5 Safety and Efficacy
  - 8.1.6 Product Profile
- 8.2 Drug B: Company
  - 8.2.1 Drug Description
  - 8.2.2 Mechanism of Action
  - 8.2.3 Clinical Trials Details
  - 8.2.4 Advantages & Disadvantages
  - 8.2.5 Safety and Efficacy
  - 8.2.6 Product Profile
- 8.3 Drug C: Company
  - 8.3.1 Drug Description
  - 8.3.2 Mechanism of Action
  - 8.3.3 Clinical Trials Details
  - 8.3.4 Advantages & Disadvantages
  - 8.3.5 Safety and Efficacy
  - 8.3.6 Product Profile
- 8.4 Drug D: Company
  - 8.4.1 Drug Description
  - 8.4.2 Mechanism of Action
  - 8.4.3 Clinical Trials Details
  - 8.4.4 Advantages & Disadvantages
  - 8.4.5 Safety and Efficacy
  - 8.4.6 Product Profile
- 8.5 Drug E: Company
  - 8.5.1 Drug Description

- 8.5.2 Mechanism of Action
- 8.5.3 Clinical Trials Details
- 8.5.4 Advantages & Disadvantages
- 8.5.5 Safety and Efficacy
- 8.5.6 Product Profile

#### 8.6 : Company

- 8.6.1 Drug Description
- 8.6.2 Mechanism of Action
- 8.6.3 Clinical Trials Details
- 8.6.4 Advantages & Disadvantages
- 8.6.5 Safety and Efficacy
- 8.6.6 Product Profile

#### 8.7 : Company

- 8.7.1 Drug Description
- 8.7.2 Mechanism of Action
- 8.7.3 Clinical Trials Details
- 8.7.4 Advantages & Disadvantages
- 8.7.5 Safety and Efficacy
- 8.7.6 Product Profile

#### 8.8 : Company

- 8.8.1 Drug Description
- 8.8.2 Mechanism of Action
- 8.8.3 Clinical Trials Details
- 8.8.4 Advantages & Disadvantages
- 8.8.5 Safety and Efficacy
- 8.8.6 Product Profile

## 9 EMERGING DRUGS

### 9.1 Key Cross Competition

#### 9.2 Emerging company

- 9.2.1 Emerging Drug A: Company
  - 9.2.1.1 Other Development Activities
  - 9.2.1.2 Clinical Development
  - 9.2.1.3 Clinical Trials Information
  - 9.2.1.4 Safety and Efficacy
  - 9.2.1.5 Advantages and Disadvantages
  - 9.2.1.6 Product Profile
- 9.2.2 Emerging Drug B: Company

- 9.2.2.1 Other Development Activities
- 9.2.2.2 Clinical Development
- 9.2.2.3 Clinical Trials Information
- 9.2.2.4 Safety and Efficacy
- 9.2.2.5 Advantages and Disadvantages
- 9.2.2.6 Product Profile
- 9.2.3 Emerging Drug C: Company
  - 9.2.3.1 Other Development Activities
  - 9.2.3.2 Clinical Development
  - 9.2.3.3 Clinical Trials Information
  - 9.2.3.4 Safety and Efficacy
  - 9.2.3.5 Advantages and Disadvantages
  - 9.2.3.6 Product Profile
- 9.2.4 Emerging Drug D: Company
  - 9.2.4.1 Other Development Activities
  - 9.2.4.2 Clinical Development
  - 9.2.4.3 Clinical Trials Information
  - 9.2.4.4 Safety and Efficacy
  - 9.2.4.5 Advantages and Disadvantages
  - 9.2.4.6 Product Profile
- 9.2.5 Emerging Drug E: Company
  - 9.2.5.1 Other Development Activities
  - 9.2.5.2 Clinical Development
  - 9.2.5.3 Clinical Trials Information
  - 9.2.5.4 Safety and Efficacy
  - 9.2.5.5 Advantages and Disadvantages
  - 9.2.5.6 Product Profile

## **10 7MM MARKET ANALYSIS**

- 10.1 7MM Market Size of Mucormycosis
- 10.2 7MM Percentage Share of Drugs Marketed for Mucormycosis
- 10.3 7MM Market Sales of Mucormycosis by Products

## **11 THE UNITED STATES MARKET OUTLOOK**

- 11.1 Market Size of Mucormycosis in United States
- 11.2 Percentage Share of Drugs Marketed for Mucormycosis in United States
- 11.3 Market Sales of Mucormycosis by Products in United States



## 11.4 Analysis of Upcoming Therapies and Impact on the Market

## 12 EU5 COUNTRIES MARKET OUTLOOK

### 12.1 Market Size of Mucormycosis in EU5

### 12.2 Market Size of Mucormycosis in Germany

#### 12.2.1 Market Size of Mucormycosis in Germany

#### 12.2.2 Percentage Share of Drugs Marketed for Mucormycosis in Germany

#### 12.2.3 Market Sales of Mucormycosis by Products in Germany

#### 12.2.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.3 Market Size of Mucormycosis in France

#### 12.3.1 Market Size of Mucormycosis in France

#### 12.3.2 Percentage Share of Drugs Marketed for Mucormycosis in France

#### 12.3.3 Market Sales of Mucormycosis by Products in France

#### 12.3.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.4 Market Size of Mucormycosis in Italy

#### 12.4.1 Market Size of Mucormycosis in Italy

#### 12.4.2 Percentage Share of Drugs Marketed for Mucormycosis in Italy

#### 12.4.3 Market Sales of Mucormycosis by Products in Italy

#### 12.4.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.5 Market Size of Mucormycosis in Spain

#### 12.5.1 Market Size of Mucormycosis in Spain

#### 12.5.2 Percentage Share of Drugs Marketed for Mucormycosis in Spain

#### 12.5.3 Market Sales of Mucormycosis by Products in Spain

#### 12.5.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.6 Market Size of Mucormycosis in United Kingdom

#### 12.6.1 Market Size of Mucormycosis in United Kingdom

#### 12.6.2 Percentage Share of Drugs Marketed for Mucormycosis in United Kingdom

#### 12.6.3 Market Sales of Mucormycosis by Products in United Kingdom

#### 12.6.4 Analysis of Upcoming Therapies and Impact on the Market

## 13 THE JAPAN MARKET OUTLOOK

### 13.1 Market Size of Mucormycosis in Japan

### 13.2 Percentage Share of Drugs Marketed for Mucormycosis in Japan

### 13.3 Market Sales of Mucormycosis by Products in Japan

### 13.4 Analysis of Upcoming Therapies and Impact on the Market

## 14 COST ANALYSIS OF MUCORMYCOSIS

## **15 GENERIC COMPETITION IN MUCORMYCOSIS MARKET**

## **16 MARKET DRIVERS**

## **17 MARKET BARRIERS**

## **18 REPORT METHODOLOGY**

### 18.1 Methodology/Research Approach

### 18.2 Data Source

#### 18.2.1 Secondary Sources

#### 18.2.2 Primary Sources

## I would like to order

Product name: Mucormycosis- Market Insights, Epidemiology and Market Forecast 2028

Product link: <https://marketpublishers.com/r/M8BFA289901EN.html>

Price: US\$ 5,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M8BFA289901EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970